Research of new GLP-1 indications underscores the potential of GLP-1s to treat more than diabetes and obesity. However, the potential to broaden GLP-1 usage is not without its challenges -- particularly GLP-1 medication shortages, high costs, and hurdles in providing coverage.
Come with questions for our speakers, Omada Health's Chief Medical Officer, Carolyn Jasik, MD, and Clinical Pharmacist Ketan Patel, PharmD from Mercer.
This webinar will cover:
What are the new indications being studied?
What do additional indications mean for health outcomes and cost?
Will this expansion impact employer coverage?
When it comes to 2025 benefits planning, what should employers be thinking about or doing to prepare for expanded indications?
